Corcept Therapeutics Incorporated (CORT)
Nasdaq: CORT · Pharmaceutical Preparations · Redwood City, CA · filing with the SEC since 2001
Grade7.3
◀ Past 8.3● Present 8.0▶ Future 5.4
Who owns Corcept Therapeutics Incorporated
As filed with the SECHolders of 5% or more
3
Blackrock, Inc. holds 8.9% of Common Stock, as its SCHEDULE 13G/A filed Oct 27, 2026 says.
Directors and officers
17
report now, of 26 people on the record since 2006. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 3 named at left.
Holders of 5% or moreshare of the class, as filed
Blackrock, Inc.
SCHEDULE 13G/A · filed Oct 27, 2026 · Common Stock · 10.9% in Jul 17, 2025
Ingalls & Snyder LLC
SCHEDULE 13G/A · filed Apr 21, 2026 · COMMON STOCK · 7.8% in Feb 21, 2025
Joseph K. Belanoff
SCHEDULE 13G/A · filed Feb 14, 2025 · Common Stock
Renaissance Technologies LLC
SCHEDULE 13G/A · filed Aug 13, 2026 · Common Stock, $0.001 par value · reported falling below 5%, from 5.47% in Feb 12, 2026
The Vanguard Group
SCHEDULE 13G/A · filed Mar 26, 2026 · Common Stock · reported falling below 5%
What CORT reports owning in othersstakes of 5% or more, and other ties
Corcept Therapeutics Incorporated reports no stake in another company in the record.
Insider tradesForm 4
113sales
2purchases
106sales on a scheduled plan
10people selling
$102Msold, in dollars
$3.3Mbought, in dollars
Open-market trades on Form 4 from Nov 4, 2025 to Nov 4, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Nov 4, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window11 of 26 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Maduck Sean | See Remarks | 22 | $25.0M | 22 | 0 | $0 |
| Mokari Atabak | Chief Financial Officer | 22 | $18.7M | 22 | 0 | $0 |
| Mahoney David L | director | 5 | $13.9M | 4 | 0 | $0 |
| Guyer William | Chief Development Officer | 19 | $13.5M | 17 | 0 | $0 |
| Belanoff Joseph K | Chief Executive Officer | 7 | $9.6M | 7 | 0 | $0 |
| Vieira Roberto Wandenkolk | President, Oncology | 13 | $8.1M | 13 | 0 | $0 |
| Wilson James N | director | 15 | $5.1M | 15 | 0 | $0 |
| Park Kimberly | director | 1 | $3.3M | 0 | 0 | $0 |
| Lyon Joseph Douglas | See Remarks | 8 | $3.2M | 6 | 0 | $0 |
| Robb Gary Charles | Chief Business Officer | 1 | $1.2M | 0 | 0 | $0 |
| Baker G Leonard Jr | director | 0 | $0 | 0 | 2 | $3.3M |